Terumo

Rank: 21

2016 Rank28 Employees20,697 Revenue:$4,731,860,850 R&D Spend:n/a Fiscal year ending:03-31-17 Click here to see all 100

Two years after Terumo scratched a distribution deal with Boston Scientific for its GlideWire urology device to go it alone, it turned to Olympus to distribute the device (having failed in its bid to merge with Olympus in the wake of that company's $17 billion accounting scandal in 2012). The company also inked a deal for a bioresorbable drug-eluting coronary stent made by France-based Arterial Remodeling Technologies, a deal that includes an exclusive buyout option. Another deal with Arterial Remodeling calls for the Japanese company to make a series of RandD investments in coronary stent technology. Terumo also launched the Misago RX self-expanding peripheral stent in the U.S., for patients with peripheral artery disease in the superficial femoral artery or proximal popliteal artery.

TERUMO® Launches Expanded Glideway™ Access Sheath Portfolio With A New Product For Minimally Invasive Urologic Procedures

Key Personnel: Shinjiro Sato, president & CEO; Hikaru Samejima, president, cardiac & vascular; Masataka Haraguchi, branch manager, Tokyo; Takanori Shibazaki, president & CEO, Terumo (China) Holdings; Kazuhisa Senshu, chief clinical & regulatory affairs officer; Fumihisa Hirose, SVP, cardiac & vascular; Paul Holbrook, president, vascular graft, president & CEO, Vascutek;

http://www.terumo.com/